News | Thrombectomy Devices | February 05, 2019

Delayed Clot Removal Still Improves Quality of Life Post-Stroke

Patients surveyed in DEFUSE 3 trial had better quality of life with thrombectomy up to 24 hours after symptom onset compared to medical therapy alone

Delayed Clot Removal Still Improves Quality of Life Post-Stroke

February 5, 2019  — Stroke survivors have better quality of life three months after their stroke if the clot that caused the stroke was mechanically removed even hours beyond the ideal treatment window compared to those treated with drugs alone. This preliminary research will be presented, Feb. 6-8 in Honolulu at the American Stroke Association’s International Stroke Conference 2019.

Researchers have found that mechanically removing a clot in stroke patients, called endovascular therapy, can limit disability from stroke. While the therapy is most effective when performed within six hours of symptom onset, it can also reduce functional deficits in patients up to 24 hours after stroke symptoms start.

In the DEFUSE 3 trial, Stanford University School of Medicine researchers studied whether stroke survivors who were treated with endovascular therapy in the late six-to-16-hour time window might have better quality of life than people treated only with standard drug therapy. They examined a subset of ischemic stroke patients who had salvageable tissue visible on brain imaging.

Researchers surveyed patients 90 days after stroke about their mobility, ability to participate in social activities, cognitive (or thinking) function and depression.

Based on results from 136 patients who completed all or some of the surveys, people treated with endovascular therapy had superior quality-of-life results in all four domains, compared to those who had medical therapy alone.

“In addition to improved functional outcomes, endovascular therapy six to 16 hours after onset preserves mental health and social capabilities critical to patients’ quality of life,” researchers said.

For more information: www.professional.heart.org


Related Content

News | Thrombectomy Devices

March 19, 2026 — Endovascular Engineering, Inc. has announced that two abstracts related to the ENGULF study and the ...

Home March 20, 2026
Home
News | Thrombectomy Devices

Jan. 15, 2026 — Boston Scientific Corp. and Penumbra, Inc. have entered into a definitive agreement under which Boston ...

Home January 19, 2026
Home
News | Thrombectomy Devices

Dec. 10, 2025 — Medtronic plc has announced the first commercial use of the Liberant thrombectomy system (Liberant) ...

Home January 07, 2026
Home
News | Thrombectomy Devices

Dec. 16, 2025 — A new study, published in the American Journal of Cardiology, found that the use of Computer Assisted ...

Home December 23, 2025
Home
News | Thrombectomy Devices

Nov. 3, 2025 — Penumbra, Inc. has announced additional results of the STORM-PE randomized controlled trial (RCT), which ...

Home November 07, 2025
Home
News | Thrombectomy Devices

Oct. 27, 2025 – Penumbra, Inc. has announced the results of the STORM-PE randomized controlled trial (RCT), which found ...

Home October 27, 2025
Home
News | Thrombectomy Devices

Sept. 2, 2025 — Imperative Care, Inc. has announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its ...

Home September 02, 2025
Home
News | Thrombectomy Devices

June 16, 2025 – Penumbra, Inc. recently announced the completion of enrollment in the STORM-PE clinical trial. This ...

Home June 16, 2025
Home
News | Thrombectomy Devices

March 24, 2025 — Imperative Care, Inc. recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of ...

Home March 24, 2025
Home
News | Thrombectomy Devices

Penumbra recently launched its Element Vascular Access System, a laser-cut hypotube sheath designed for venous ...

Home January 30, 2025
Home
Subscribe Now